Abstract
In this study, bilosome as a drug delivery system for insulin was studied. Two bilosomal preparations were formulated and assessed. One was prepared using a lipid extract from Soya beans seed (SBE), Palmitic acid (PA) and cholesterol (CH ) in the ratio of 0.25:1:1 w/w designated as BI while the other (BII) contained PA and CH as the lipid entity at the ratio of 1:1 w/w. Each of the preparations contained 0.5% of sodium deoxycholate (SDC) and soluble insulin. BI was given orally only, while BII was administered subcutaneously, intraperitoneally and orally to different groups of streptozotocin-induced diabetic male rats, and the blood glucose levels were measured at predetermined time intervals. The results of the studies showed that oral administration of BI and BII produced blood glucose reduction, which could mimick endogenous release of insulin with prolonged activity, although, less blood sugar lowering compared with parental administration. BI (oral I) containing SBE had greater reduction of blood glucose than BII (oral II) ,showing that SBE increased the bioavailability of insulin. Bilosomal insulin formulation could provide a good oral delivery system for insulin that would affect the entero-insular axis similar to endogenous insulin.
Keywords: Bilosome, insulin, blood glucose reduction, drug delivery system, bioavailability, formulation
Current Drug Delivery
Title: Evaluation of the Pharmacodynamic Activity of Insulin from Bilosomal Formulation
Volume: 6 Issue: 4
Author(s): I. J. Ayogu, O. Ogbonna, C. I. Ayolugbe and A. A. Attama
Affiliation:
Keywords: Bilosome, insulin, blood glucose reduction, drug delivery system, bioavailability, formulation
Abstract: In this study, bilosome as a drug delivery system for insulin was studied. Two bilosomal preparations were formulated and assessed. One was prepared using a lipid extract from Soya beans seed (SBE), Palmitic acid (PA) and cholesterol (CH ) in the ratio of 0.25:1:1 w/w designated as BI while the other (BII) contained PA and CH as the lipid entity at the ratio of 1:1 w/w. Each of the preparations contained 0.5% of sodium deoxycholate (SDC) and soluble insulin. BI was given orally only, while BII was administered subcutaneously, intraperitoneally and orally to different groups of streptozotocin-induced diabetic male rats, and the blood glucose levels were measured at predetermined time intervals. The results of the studies showed that oral administration of BI and BII produced blood glucose reduction, which could mimick endogenous release of insulin with prolonged activity, although, less blood sugar lowering compared with parental administration. BI (oral I) containing SBE had greater reduction of blood glucose than BII (oral II) ,showing that SBE increased the bioavailability of insulin. Bilosomal insulin formulation could provide a good oral delivery system for insulin that would affect the entero-insular axis similar to endogenous insulin.
Export Options
About this article
Cite this article as:
Ayogu J. I., Ogbonna O., Ayolugbe I. C. and Attama A. A., Evaluation of the Pharmacodynamic Activity of Insulin from Bilosomal Formulation, Current Drug Delivery 2009; 6 (4) . https://dx.doi.org/10.2174/156720109789000573
DOI https://dx.doi.org/10.2174/156720109789000573 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genomic Linkage Between Alzheimer's Disease and Type 2 Diabetes
CNS & Neurological Disorders - Drug Targets Diabetes and Mortality in Acute Coronary Syndrome: Findings from the Gulf COAST Registry
Current Vascular Pharmacology The Impact of Mitochondrial DNA and Nuclear Genes Related to Mitochondrial Functioning on the Risk of Parkinson’s Disease
Current Genomics Prevention and Treatment of Diabetic Retinopathy: Evidence from Clinical Trials and Perspectives
Current Diabetes Reviews Protein-Tyrosine Phosphatase 1B (PTP1B): A Novel Therapeutic Target for Type 2 Diabetes Mellitus, Obesity and Related States of Insulin Resistance
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Connecting Parkinsons Disease and Drug Addiction: Common Players Reveal Unexpected Disease Connections and Novel Therapeutic Approaches
Current Pharmaceutical Design Circulatory Estrogen Level Protects Against Breast Cancer in Obese Women
Recent Patents on Anti-Cancer Drug Discovery High-Density Lipoprotein-Raising Strategies: Update 2010
Current Pharmaceutical Design Polymorphisms of the Aldose Reductase Gene and Susceptibility to Diabetic Microvascular Complications
Current Medicinal Chemistry Systemic Approach to the Study of Complex Bone Disorders at the Whole- Genome Level
Current Genomics Changes in the Density of Corneal Endothelial Cells in Elderly Diabetic Patients After Combined Phacovitrectomy and Ex-PRESS Glaucoma Implants
Current Pharmaceutical Biotechnology Cardiometabolic Risk Related to the Association of hypertriglyceridemia-Low HDLc
Current Pharmaceutical Design Atherosclerotic Process in Seroreverter Children and Adolescents Exposed to Fetal Antiretroviral Therapy
Current HIV Research Anti-Diabetic Effects of Isolated Lipids from Natural Sources through Modulation of Angiogenesis
Current Molecular Pharmacology Molecular Mechanisms, Emerging Etiological Insights and Models to Test Potential Therapeutic Interventions in Alzheimers Disease
Current Alzheimer Research Immunological Aspects of IgG4-Related Disease
Current Immunology Reviews (Discontinued) Hypertensive Heart Disease and the Role of Aldosterone Antagonists
Current Hypertension Reviews Insulin Resistance, Inflammation and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of the Stress-Related Anti-Inflammatory Hormones ACTH and Cortisol in Atherosclerosis
Current Vascular Pharmacology Biomarkers of Diabetic Nephropathy, the Present and the Future
Current Diabetes Reviews